Concerning this particular malignancy, recent molecular imaging and immunohistochemistry studies focused on its expression of prostate-specific membrane antigen (PSMA, also known as carboxypeptidase type II), reporting a high expression of this transmembrane protein on the ACC tumor cell membrane, an optimal diagnostic accuracy of PSMA-targeted PET imaging, and the potential for PSMA to be an effective target for radioligand therapy [29,30]. The gene discussed is FOLH1; the disease is neoplasm.